Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
709 ARTICLES BY Jacob Bell
- Sept. 24, 2018 Gilead creates subsidiary to sell generic versions of hep C blockbusters
- Sept. 24, 2018 J&J still has much to explore with continuous manufacturing
- Sept. 24, 2018 For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'
- Sept. 24, 2018 Sarepta clears up clinical hold for gene therapy
- Sept. 21, 2018 Sarepta strikes out again with European regulators
- Sept. 20, 2018 Phase 3 win underscores that Astellas is more than Xtandi
- Sept. 18, 2018 Novo's reorganizing claims more jobs, with R&D set to lose 400
- Sept. 17, 2018 More data bolster AstraZeneca's 3-in-1 inhaler as other assets face setbacks
- Sept. 13, 2018 Inbrija delay poses question: How far can Acorda fall?
- Sept. 11, 2018 FINCH-2 data bodes well for Gilead, Galapagos JAK inhibitor
- Sept. 11, 2018 Merck's pneumonia antibiotic stacks up in pivotal study
- Sept. 7, 2018 As EpiPen struggles, Walgreens, Kaleo ink Auvi-Q partnership
- Sept. 6, 2018 Akcea to reduce workforce 10% following Waylivra rejection
- Sept. 6, 2018 Health systems roll out generic manufacturing company to meet hospital needs
- Sept. 6, 2018 Gilead, Galapagos build case for JAK inhibitor with Phase 2 win
- Sept. 5, 2018 Generics group says branded drugmakers blocking $13B in annual savings
- Sept. 5, 2018 With 12 more patients dosed, Bluebird reinforces strong profile for Lenti-D
- Sept. 4, 2018 BioPharma Dive's 10 hottest stories of the summer
- Aug. 31, 2018 Merck's virology business needs a boost. It may not get that from 2 new HIV drugs
- Aug. 31, 2018 What you need to know about the evolving regulatory landscape
- Aug. 30, 2018 Catalent's growth blemished by weaker Softgel performance
- Aug. 30, 2018 Pfizer shutters DMD program following failed study
- Aug. 30, 2018 Despite new approval, Bayer continues to face hemophilia headwinds
- Aug. 29, 2018 In a summer of C-suite departures, a week of commercial hires
- Aug. 28, 2018 Waylivra rejection raises questions about Ionis, Akcea ability to close